Methysergide
| |
| Methysergide
| |
| Systematic (IUPAC) name | |
| 1-Methyl-d-lysergic acid-(1-hydroxybut-2-yl)amide | |
| Identifiers | |
| CAS number | |
| ATC code | N02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H27N3O2 |
| Mol. mass | 353.458 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Methysergide (UML-491) is a prescription drug used for prophylaxis of migraine headaches and is sold under the brand names Sansert and Deseril in 2mg dosages. Methysergide was approved by the FDA in 1962. Its molecular structure is closely related to that of LSD. It is a 5-HT (serotonin) antagonist. It is a receptor antagonist for the 5-HT receptor 2C[1].
Methysergide is one of the most effective medications for the prevention of migraine, but not for the treatment of an acute attack. It has a known side effect, retroperitoneal fibrosis[2], which is severe, although uncommon. Novartis withdrew it from the U.S. market after taking over Sandoz, but currently lists it as a product.
Like LSD, methysergide also produces psychedelic and hallucinogenic effects above a dosage of about 4mg.[3] Full effects are felt with dosages of 8-20mg.[citation needed]
See also
References
- ↑ Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. Page 187
- ↑ emedicine.com (2002)
- ↑ L. Bender (1970): "Children's Reactions to Psychotomimetic Drugs", Psychotomimetic Drugs, pp. 265-273]
External links
- Novartis Sansert site.
- Novartis Sansert product description.
- Migraines.org More detailed information on methysergide.
- neurologychannel.com, general information on migraines.
Ergolines | |
|---|---|
| Lysergic acid derivatives | Bromocriptine, Cabergoline, Ergine, Ergonovine, Ergotamine, Lysergic acid, Lysergol, LSD, D-Lysergic acid hydroxyethylamide, Lisuride, Methergine, Methysergide, Pergolide |
| Hallucinogenic lysergamides | AL-LAD, ALD-52, BU-LAD, CYP-LAD, DAL, DAM-57, Ergonovine, ETH-LAD, LAE-32, LSD, LPD-824, LSM-775, D-Lysergic acid N-(α-hydroxyethyl)amide, Methylergonovine, MLD-41, PARGY-LAD, PRO-LAD |
| Other ergolines | Ergoline |
| Natural sources | Argyreia nervosa, Claviceps spp., Ipomoea tricolor, Ipomoea violacea, Rivea corymbosa |
Antimigraine preparations (N02C) | |
|---|---|
| Ergot alkaloids | Dihydroergotamine • Ergotamine • Methysergide • Lisuride |
| Corticosteroid derivatives | Flumedroxone |
| Selective serotonin (5-HT1) agonists | Triptans (Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan) |
| Other antimigraine preparations | Pizotifen • Clonidine • Topiramate • Iprazochrome • Dimetotiazine • Oxetorone |
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
